US Patent

US11400092 — Methods of treating myeloproliferative disorders

Method of Use · Assigned to Impact Biomedicines Inc · Expires 2039-09-24 · 13y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of treating myeloproliferative disorders by mitigating thiamine deficiency.

USPTO Abstract

The present disclosure provides methods of mitigating thiamine deficiency.

Drugs covered by this patent

Inrebic (FEDRATINIB HYDROCHLORIDE) · Bristol-Myers Squibb

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3409`	—	Inrebic

Patent Metadata

Patent number: US11400092
Jurisdiction: US
Classification: Method of Use
Expires: 2039-09-24
Drug substance claim: No
Drug product claim: No
Assignee: Impact Biomedicines Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.